A B S T R A C T We studied the effect ofseveral doses of atropine on the serum gastrin and pancreatic polypeptide responses to vagal stimulation in healthy human subjects. Vagal stimulation was induced by sham feeding. To eliminate the effect of gastric acidity on gastrin release, gastric pH was held constant (pH 5) and acid secretion was measured by intragastric titration. Although a small dose of atropine (2.3 ,ug/kg) significantly inhibited the acid secretory response and completely abolished the pancreatic polypeptide response to sham feeding, this dose of atropine significantly enhanced the gastrin response. Higher atropine doses (7.0 and 21.0,g/kg) had effects on gastrin and pancreatic polypeptide release which were similar to the 2.3-pAg/kg dose. Atropine (0.78 and 2.3 ,ug/kg) without sham feeding significantly inhibited basal acid secretion and also led to significant increases in serum gastrin above basal levels. The gastrin response to sham feeding with 2.3 ug/kg atropine was significantly greater than the sum of the gastrin responses to sham feeding alone and to 2.3 ,ug/kg atropine alone, indicating potentiation ofvagal gastrin release by atropine. We conclude: (a) Unlike vagally mediated gastric acid secretion and pancreatic polypeptide release which can be blocked by atropine, vagal gastrin release is potentiated by atropine. This observation suggests the existence of a vagal-cholinergic pathway which normally (i.e., in the absence of atropine) inhibits gastrin release. (b) Because atropine (without sham feeding) increased basal gastrin levels, it is likely that the cholinergic pathway which inhibits gastrin release is active even when the vagus nerve is not stimulated by sham feeding.
INTRODUCTION
The effect of atropine on vagally mediated gastrin release in man is poorly understood. In a recent study, Receivedfor publication 21 April 1978 and in revisedform 11 August 1978. 294 the rise in serum gastrin concentration induced by insulin hypoglycemia was further increased by atropine premedication (1) . In addition, several workers have shown that atropine increases the serum gastrin concentration after an eaten meal (2) (3) (4) . These observations, together with the fact that basal and postprandial gastrin levels rise after vagotomy (5-7), have led to speculation that the vagus nerve can inhibit, as well as stimulate, gastrin release.
For several reasons, however, none of these observations proves that the vagus nerve actually inhibits gastrin release under normal circumstances. First, studies using insulin hypoglycemia as a vagal stimulant must be interpreted with caution because there is evidence that hypoglycemic gastrin release is nonvagal (8) (9) (10) . For example, the gastrin response to hypoglycemia persists after a complete vagotomy (8, 9) . Second, meal studies that have been done with atropine (2-4) are not definitive because atropine reduces acid secretion, and the resulting higher antral pH would facilitate gastrin release in response to any stimulant. This criticism is also pertinent to vagotomy studies in which gastric pH was not controlled. Third, many studies that have been done with atropine are inconclusive because the effect of atropine alone was not studied. If atropine alone increased serum gastrin concentrations, higher meal-or insulin-stimulated gastrin levels would be expected after atropine simply on an additive basis.
The purpose of our studies was to evaluate more definitively the effect of atropine on vagal gastrin release in man. To do this, we employed a method of vagal stimulation that acts only through the vagus nerve: sham feeding (11, 12 3 . Under fluoroscopic guidance the triple lumen tube was positioned so that the tip of tube 3 was in the gastric antrum. To initiate each experiment 50 ml saline (300 mosm/kg), adjusted to pH 5.0, was infused into the stomach through tube 3. This was followed by a continuous intragastric saline infusion (pH 5.0) through tube 1 at a rate of 4.2 ml/min (Brinkman Peristalic Pump, Desaga Inc., Heidelberg, Germany). Gastric pH was held constant and acid secretion measured by in vivo intragastric titration. Every 2 min, 0.5 ml gastric fluid was removed through tube 3 and the pH was determined. Sodium bicarbonate (0.3 N) was infused into the stomach through tube 2 at a rate sufficient to maintain gastric pH at 5.0. The number of milliequivalents of bicarbonate added is equal to the number of milliequivalents of acid secreted (13) . Previous studies have shown (14) , and it was confirmed again in this study, that this continuous intragastric saline infusion has no effect on basal serum gastrin concentrations.
Atropine. After a 60-min control period, atropine sulfate (Wyeth Laboratories, Philadelphia, Pa.) was injected intramuscularly in doses of 0 (saline control), 0.78,2.3,7.0, and 21.0 ug/kg total body weight. One atropine dose was given per study day, and the order in which the atropine doses were given was randomized.
Sham feeding (SF).' 15 min after atropine (or saline) was injected, subjects chewed for 30 min, but did not swallow, an appetizing meal consisting of sirloin steak, french-fried potatoes, and water (15) . Meals were cooked in a separate building so that subjects could not see or smell food until time for SF. Subjects were trained in preliminary experiments not to swallow food. During all experiments, gastric aspirates were examined for swallowed food and none was found.
Gastrin and human pancreatic polypeptide (HPP) measurement. Venous blood was collected through an indwelling catheter kept open by a slow intravenous 0.15 M NaCl infusion. Blood was allowed to clot and serum was stored at -200C until assayed.
Serum gastrin concentrations were measured by radioimmunoassay. All samples were tested in duplicate in the same assay. Antibody 1296, rabbit antigastrin prepared by immunization with gastrin conjugated to bovine serum albumin, was used at a final dilution of 1:300,000. Human heptadecapeptide gastrins (HG-17-I and HG-17-II) and human big gastrins (HG-34-I and HG-34-II) are measured with this antiserum, big gastrins being approximately two-thirds as potent as heptadecapeptides (16) . Cross reactivity with porcine cholecystokinin was <5% (17 (20) .
RESULTS
Gastrin SF without atropine. As shown in Fig. 1 (left were more than threefold greater than the IGR to SF without atropine (P < 0.05 for each dose) (Table II) . IGR after SF with 2.3, 7, or 21 ,tg/kg atropine were not significantly different from each other.
HPP SF led to significant rises in serum HPP concentrations from basal levels of 89+10 pg/ml to a peak level of 136±20 pg/ml at 37.5 min (P < 0.01). The integrated HPP response(s) (IPPR) to SF averaged 1.40±0.38 ng min/ml (Table II) . Atropine (2.3 .ug/kg) completely abolished the IPPR to SF. In fact, the negative IPPR in Table II indicates that this dose of atropine reduced HPP below basal levels. Higher atropine doses had similar effects on HPP release during SF. IPPR after SF with 2.3, 7, or 21 ,ug/kg atropine were not significantly different from each other.
Gastric acid secretion and gastric volume As shown in Table II , the rate of gastric acid secretion in response to SF was progressively suppressed by increasing doses of atropine. In addition (although not shown in Table II ), 2.3 ug/kg atropine without SF significantly reduced basal acid secretion in all nine subjects (P < 0.005). In the four subjects studied with 0.78 ug/kg, atropine significantly reduced basal acid secretion (P < 0.01). It should be recalled that gastric pH was kept constant, in spite of different rates of acid secretion, by intragastric titration with sodium bicarbonate.
The volume offluid aspirated from the stomach at the end of the experiment (final gastric volume) increased in a dose-related fashion (Table II) (Table II) . The 0.78-,ug/kg atropine dose had no effect on pulse rate.
DISCUSSION
A major finding in this study was that small doses of atropine (0.78 and 2.3 Ag/kg) led to graded and significant rises in basal serum gastrin levels. Although these doses of atropine significantly inhibited gastric acid secretion, the effect of atropine on gastrin release was not mediated by a decrease in gastric acidity, because gastric pH was controlled by intragastric titration. Assuming that atropine suppressed gastric secretion by blocking cholinergic-muscarinic receptors in the stomach (21) , it is most likely that atropine increased gastrin levels by blocking a cholinergic pathway which normally (i.e., in the absence of atropine) inhibits gastrin release in the basal state.
Previous workers have not found an increase in basal serum gastrin concentrations after atropine (2, 3, 22) , and some actually found a decrease (4, 23) . However, our experiments cannot be compared directly with previous studies because we used smaller doses of atropine and because antral pH was not held constant in these other studies. In addition, it is possible that the slight amount of gastric distention in our studies (-50 ml) at pH 5.0 initiated local or vagovagal reflexes, which in the presence of atropine, resulted in antral gastrin release.
Atropine did more than raise basal gastrin concentrations. The shaded area in Fig. 1 represents the extent to which 2.3 ,ug/kg atropine potentiated the gastrin response to SF and therefore the extent to which the vagus had inhibited gastrin release during SF without atropine. Thus, when activated by SF, the vagus nerve appears to suppress gastrin release by a cholinergic, atropine-sensitive pathway. The exact location of the putative vagal-cholinergic pathway that inhibits gastrin release is not clear from these studies, although it is convenient to envision an inhibitory neuron in the vicinity of antral gastrin cells. Because 2.3 ,ug/kg atropine slowed the pulse rate slightly, the possibility that this dose of atropine was acting as a parasympathomimetic drug (24) , rather than as a muscarinic antagonist, needs to be considered. However, we feel that this dose of atropine was not acting as a cholinergic agonist drug for several reasons. First, administration of cholinergic agonist drugs does not release gastrin (25) (26) (27) (28) . Second, 2.3 ug/kg atropine abolished vagal release of pancreatic polypeptide, a hormone known to be released by vagal-cholinergic stimulation (29) . Third, atropine doses >2.3 ,g/kg, which led to clear-cut antimuscarinic effects (tachycardia, dry mouth), had similar effects on gastrin and HPP release as the 2.3-,ug/kg dose, which favors a similar pharmacologic mode of action. And fourth, a dose of atropine <2.3 ,ug/kg released gastrin and inhibited acid secretion without changing the pulse rate. This latter observation also suggests that the inhibitory pathway for gastrin release and the gastric parietal cells are more sensitive to atropine than the heart.
Because SF without atropine led to significant rises in serum gastrin concentrations, it is apparent that the vagus nerve stimulates, as well as inhibits, gastrin release. We found that atropine doses as high as 21 ,ug/kg led to an increase in the amount of gastrin released during SF. This suggests that the vagus releases gastrin by a pathway that is atropine-resistant and that may therefore be noncholinergic.
To summarize, vagal activation by SF stimulates the release of HPP and gastrin. In contrast to vagally mediated HPP release and gastric acid secretion, which are inhibited by atropine, vagal gastrin release is potentiated by atropine, supporting the existence of a vagal-cholinergic inhibitory pathway for gastrin release. In addition, because atropine alone significantly increased serum gastrin above basal Atropine and Vagal Hormone Release 297 levels, this putative inhibitory cholinergic pathway may be active even when the vagus nerve is not stimulated by SF.
